• Our CiPA Instruments

    Patchliner & SyncroPatch 384PE (CiPA ion channel working group); CardioExcyte 96 (CiPA myocyte working group)

  • CiPA hERG Protocol

    This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.

  • HTS CiPA hERG Assay

    Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE

  • Myocyte & Ion Channel Effects

    Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)

  • Gigaseal HTS patch clamp

    CiPA-specified cardiac ion channels recorded at high throughput

  • Gigaseal HTS patch clamp

    High throughput recordings of cardiac ion channels at physiological temperature

  • CardioExcyte 96 screening tool

    CardioExcyte 96 with integrated liquid handling for cardiac safety screening

Cardiomyocytes - "Impedance and EFP recordings of iCell Cardiomyocytes² on the CardioExcyte 96"

Icon CE   CardioExcyte 96 Application Note   logo pdf   (2.8 MB)
Cells were kindly provided by Cellular Dynamics.

 Summary:

Cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) are gaining interest in cardiac safety screening. Given their recapitulation of native behavior, availability, ease of use and standardized production, they are likely to provide a viable alternative to acutely isolated cardiomyocytes to assess the pro-arrhythmic potentials of drug candidates. Although automated patch clamp can provide excellent information about the effects of compounds on cardiac ion channels and possible effects on the cardiac action potential, other outputs such as extracellular field potential (EFP) and impedance, also provide crucial and complementary information about complex physiological parameters such as beat rate, amplitude and duration. The CardioExcyte 96 is a new hybrid screening tool combining impedance (cell contractility) and EFP recordings. These measurements are non-invasive, label free and have a temporal resolution of 1 ms. The recordings are made from cells within a network thus providing a physiologically relevant environment for measuring drug-induced changes in contractileparameters. This hybrid technology is a high-throughput screening tool which permits the reliable investigation of short- and long-term pharmacological effects.Here we present data recorded on the CardioExcyte 96 using iCell® Cardiomyocytes2 from Cellular Dynamics International (CDI). When handled according to the manufacture’s instructions, impedance and EFP signals were stable 4 days afterplating and compound effects could be robustly measured and analyzed.

Back to Overview

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok